The antiangiogenic monoclonal antibody aflibercept in association with fluorouracil and irinotecan improves the survival of patients with metastatic colorectal cancer (mCRC) treated previously with oxaliplatin-based therapy. Multiple reports raised the hypothesis that the concomitant use of antiresorptive drugs and antiangiogenic drugs may increase the risk of osteonecrosis of the jaw (ONJ). Some reports have been published regarding cases of ONJ during treatment with bevacizumab for mCRC.

Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district

PINTA, Francesco;SPADI, ROSELLA;MECCA, Caterina;ZANINI, Marcello;
2016

Abstract

The antiangiogenic monoclonal antibody aflibercept in association with fluorouracil and irinotecan improves the survival of patients with metastatic colorectal cancer (mCRC) treated previously with oxaliplatin-based therapy. Multiple reports raised the hypothesis that the concomitant use of antiresorptive drugs and antiangiogenic drugs may increase the risk of osteonecrosis of the jaw (ONJ). Some reports have been published regarding cases of ONJ during treatment with bevacizumab for mCRC.
106
2 supplemento
74
77
Ponzetti, Agostino; Pinta, Francesco; Spadi, Rosella; Mecca, Caterina; Fanchini, Laura; Zanini, Marcello; Ciuffreda, Libero; Racca, Patrizia
File in questo prodotto:
File Dimensione Formato  
Jaw osteonecrosis.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 579.79 kB
Formato Adobe PDF
579.79 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1582855
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 11
social impact